NCT03194321 - Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions

End Stage Renal Disease

Interventions

DRUG

Tacrolimus Extended-Release Oral Capsule

Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.

Trial Locations (1)

90048

Cedars Sinai Medical Center, Los Angeles